Is Survodutide FDA approved?
No. This profile records Survodutide as not FDA approved and for research use only.
MORE CONTEXT ›
Review the regulatory and source details on this page for the current context.
Metabolic CATEGORY
Survodutide
THE DUAL ACTION
BI 456906
Survodutide is a dual agonist that activates both GLP-1 and glucagon receptors. This dual action may provide superior weight loss compared to GLP-1-only drugs like Semaglutide, while also improving liver health and metabolic markers. It's currently in late-stage clinical trials for both obesity and fatty liver disease.
Survodutide
Survodutide
Survodutide
Survodutide Evidence Snapshot
How these guides are reviewed
REGULATORY STATUS
Not FDA approved · research use only
DOSING GUIDANCE
Reviewed by our clinical team
LINKED EVIDENCE
Sources pending
CONTENT UPDATED
Sep 1, 2026
Dose and schedule recommendations shown below come from The Peptide App Clinical Team. Research links are provided so readers can inspect the supporting evidence directly. Review the sources.
Quick Answers About Survodutide
What dose does The Peptide App Clinical Team recommend for Survodutide?
Dose: 0.6mg to 4.8mg weekly (dose escalation).
MORE CONTEXT ›
Schedule: daily. Cycle: Weekly injection, continuous use. This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.
What research supports this Survodutide guide?
No linked research sources are currently available on this guide.
MORE CONTEXT ›
Treat the profile as provisional until supporting sources are published.
Those seeking maximum weight loss potential
People with fatty liver disease (NASH/MAFLD)
Individuals who plateau on single-agonist GLP-1s
Early adopters of next-gen metabolic therapies
Survodutide Research
Live research temporarily unavailableThe live research feed did not return papers for this page. The curated references below remain available for crawlable source context.